Mechanism and role of regulated cell death in tumor immunity and immunotherapy
Cancer Communications · 2025-11 · 45 (11) · 1456-1495
DOI: 10.1002/cac2.70064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 26.09.2025. Verfasst von Jingwen Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Regulated Cell Death. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 429 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Hunan Province, Changsha Municipal Natural Science Foundation, Hunan Province Young Backbone Teachers Training and Support Program for General Universities.
Abstract (Originalsprache)
Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to their ability to release damage‐associated molecular patterns (DAMPs), enhance antigen presentation, and remodel the tumor immune microenvironment, thereby activating anti‐tumor immune responses. A number of studies have shown that precise induction of these pathways by small molecules or nanoparticles can reverse the resistance to chemoradiotherapy and ICIs, promote the transformation of “cold tumors” to “hot tumors,” and ultimately establish durable immune memory. This article systematically reviewed the key mechanisms and immunomodulatory functions of five types of non‐apoptotic RCD (ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis), discussed the related treatment strategies, and prospects for the future application in combination with existing immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
- Department of Pathology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
ORCID-Profile: Jingwen Hu, Luqing Zhao
Förderung
- Natural Science Foundation of Hunan Province
- Changsha Municipal Natural Science Foundation
- Hunan Province Young Backbone Teachers Training and Support Program for General Universities
- Graduate Education and Teaching Reform Project of Central South University
Zitieren
APA
Hu, J., Li, Y., Lian, B., Mao, Y., & Zhao, L. (2025). Mechanism and role of regulated cell death in tumor immunity and immunotherapy. Cancer Communications, 45(11), 1456-1495. https://doi.org/10.1002/cac2.70064
Vancouver
Hu J, Li Y, Lian B, Mao Y, Zhao L. Mechanism and role of regulated cell death in tumor immunity and immunotherapy. Cancer Communications. 2025;45(11):1456-1495. doi:10.1002/cac2.70064
BibTeX
@article{Hu2025,
author = {Hu, Jingwen and Li, Yan and Lian, Bingjie and Mao, Yitao and Zhao, Luqing},
title = {Mechanism and role of regulated cell death in tumor immunity and immunotherapy},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {11},
pages = {1456--1495},
doi = {10.1002/cac2.70064}
}
EUVIMED